Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
3370 Results for "
Complex
" in MedChemExpress (MCE) Product Catalog:
Products (3370)
3370 Results for "Complex" in MCE Product Catalog:
Cat. No.: HY-N10612
CAS No.: 26577-85-5
Category:
Target:
Cat. No.: HY-P10409
CAS No.: 1191923-93-9
Synonyms: Small humanin-like peptide 2
Domaines de recherche:
Cat. No.: HY-P11223
Target:
Domaines de recherche:
Cat. No.: HY-P2832B
Target:
Domaines de recherche:
Acyl-coenzyme A Synthetase, Pseudomonas sp. (EC 6.2.1.3) belongs to the ligase family and can activate the breakdown of complex fatty acids. Acyl-coenzyme A Synthetase, Pseudomonas sp. (EC 6.2.1.3) catalyzes the production of fatty acyl-CoA in a two-step process via an adenylate intermediate. Acyl-coenzyme A Synthetase, Pseudomonas sp. (EC 6.2.1.3) catalyzes the pre-reaction of fatty acid β-oxidation and can also be incorporated into phospholipids. Acyl-coenzyme A Synthetase, Pseudomonas sp. (EC 6.2.1.3) protein is involved in regulating and promoting the transport of long-chain fatty acids in mammalian cells.
Cat. No.: HY-W611371
CAS No.: 61694-81-3
Target:
Domaines de recherche:
FP802 is an orally active potent TwinF interface inhibitor that disrupts and detoxifies the NMDAR/TRPM4 death complex. FP802 exerts powerful neuroprotective effects in the 5xFAD mouse model of Alzheimer’s disease (AD) by preventing cognitive decline, preserving neuronal structural integrity, reducing amyloid-β plaque formation, and mitigating mitochondrial pathology . FP802 stops loss of motor neurons, reduces serum neurofilament light chain (NfL) levels, improves motor performance, and extends life in a mouse model of amyotrophic lateral sclerosis (ALS). FP802 can be used for AD and ALS research .
Cat. No.: HY-147099
Pureté: 97.8%
dTAG-47-NEG is an inactive bifunctional negative control PROTAC and also the diastereomer of dTAGV-1 (HY-145514D). dTAG-47-NEG does not reduce the level of BCL11A-FKBP12 F36V, nor does it induce the degradation of BCL11A-FKBP12 F36V, proteins tagged with FKBP12 F36V, wild-type FKBP12, FKBP12 F36V-KRAS G12V or FKBP12 F36V-EWS/FLI. dTAG-47-NEG exerts no antiproliferative effect in cancer cells .
Cat. No.: HY-156084
CAS No.: 2809353-52-2
LL-K9-3 is a selective CDK9-cyclin T1 HyT degrader, with DC50 values of 0.662 μM and 0.589 μM for CDK9 and Cyclin T1, respectively. LL-K9-3 lacks an E3 ligand moiety and induces polyubiquitination and proteasome-mediated synchronous degradation of CDK9 and cyclin T1 via a hydrophobic tag-mediated mechanism. LL-K9-3 downregulates the protein levels of androgen receptor (AR) and c-Myc, and exhibits antiproliferative and pro-apoptotic (apoptosis) activity in prostate cancer cells. LL-K9-3 can be used in studies related to prostate cancer .
Cat. No.: HY-161162
CAS No.: 2387510-81-6
Synonyms: CFT-2139
Target:
Domaines de recherche:
aTAG 2139 (CFT-2139) is a bifunctional tag-targeted PROTAC-class degrader that induces the degradation of the MTH1 aTAG fusion protein by recruiting cereblon, with a DC50 of 1.1 nM (in Jurkat T cells). aTAG 2139 is applicable to the research of CD19-positive cancers .
Cat. No.: HY-174920
CAS No.: 1797406-70-2
Target:
Domaines de recherche:
PROTAC BRD4 Degrader-34 (1797406-70-2) is a VHL-recruiting PROTAC BRD4 degrader. PROTAC BRD4 Degrader-34 induces degradation of the short isoform of BRD4 and can be used in studies of BRD4-related diseases and targeted protein degradation .
Cat. No.: HY-181305
CAS No.: 2653338-60-2
Target:
Domaines de recherche:
PROTAC EZH2 Degrader-10 is a selective PROTAC protein degrader targeting EZH2. PROTAC EZH2 Degrader-10 can be used for the research of cancer .
Cat. No.: HY-181606
Domaines de recherche:
Cyclo (phg-isoDGR-k)-PEG4-non-cleavable-SAR405838 is a dual MDM2 and α5β1 integrin modulator. Cyclo (phg-isoDGR-k)-PEG4-non-cleavable-SAR405838 acts as an antiproliferative agent, apoptosis inducer and cell cycle regulator, induces reactivation of p53 and upregulation of p21, redistributes glioblastoma cells from the G0/G1 phase to the G2/M phase, and enhances apoptosis. Cyclo (phg-isoDGR-k)-PEG4-non-cleavable-SAR405838 is applicable to the research of glioblastoma .
Cat. No.: HY-183854
CAS No.: 223784-75-6
AG-12286 is a pan-CDK inhibitor with an IC50 value of 2 nM against cdk1/cyclin B, 6 nM against cdk2/cyclin E, and 12 nM against cdk4/cyclin D. AG-12286 is 1000-fold more selective for the CDK family than for PKC. AG-12286 can be used in cancer research .
Cat. No.: HY-N11913
CAS No.: 53377-54-1
Target:
Cat. No.: HY-P1958
CAS No.: 667899-73-2
Target:
Domaines de recherche:
Cat. No.: HY-W509797
CAS No.: 21618-92-8
Target:
Drug Metabolite TNF Receptor IKK NF-κB Autophagy NOD-like Receptor (NLR) NADPH Oxidase Keap1-Nrf2
Domaines de recherche:
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone is an intestinal microbiota metabolite of (-)-Epicatechin (HY-N0001). 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone downregulates TNF-α-stimulated phosphorylation of IKK and IκBα, inhibits the transcriptional activation of NF-κB, and suppresses the expression of adhesion molecules and chemokines. 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone promotes autophagy, alleviates oxidative stress, maintains osteoblast differentiation, induces G1 phase arrest, inhibits adipogenesis, and scavenges ABTS free radicals. 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone inhibits the adhesion of uropathogenic Escherichia coli to bladder epithelial cells; when used in combination with Curcumin (HY-N0005), it downregulates the NLRP3 and NOX2/Nrf2 signaling pathways, thereby reducing microglial activation. 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone can be used in research related to diabetes, atherosclerosis, osteoporosis, obesity, neurodegenerative diseases involving microglial activation, and urinary tract infections .
Cat. No.: HY-P70656
Pureté: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: FCGRT; Major Histocompatibility Complex Class I-Like Fc Receptor; Fc Gamma Receptor And Transporter; Neonatal Crystallizable Fc Receptor FcRn Splice Variant 6; Neonatal Fc Receptor; Neonatal Crystallizable Fc Receptor FcRn Splice Variant 5; FcRn; Neonatal
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P72710
Pureté: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CD74; Ia-Associated Invariant Chain; Prev. DHLAG; HLA-DR-Gamma; CLIP; Ia Antigen-Associated Invariant Chain; CD74 Antigen (Invariant Polypeptide Of Major Histocompatibility Complex, Class II Antigen-Associated); CD74 Antigen; CD74 Molecule, Major Histocom
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P73522
Pureté: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: FCGRT; Major Histocompatibility Complex Class I-Like Fc Receptor; Fc Gamma Receptor And Transporter; Neonatal Crystallizable Fc Receptor FcRn Splice Variant 6; Neonatal Fc Receptor; Neonatal Crystallizable Fc Receptor FcRn Splice Variant 5; FcRn; Neonatal
Species:
Human
Source:
HEK293
Cat. No.: HY-P74841
Pureté: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: NFKBIA; MAD-3; Prev. NFKBI; Major Histocompatibility Complex Enhancer-Binding Protein MAD3; NF-Kappa-B Inhibitor Alpha; IkB-Alpha; IkappaBalpha; Nuclear Factor Of Kappa Light Chain Gene Enhancer In B-Cells; IKBA; EDAID2; I-Kappa-B-Alpha; MAD3; NFKB Inhibi
Species:
Human
Source:
E. coli
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
